• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Denmark·Healthcare·CHEMM.CO
Share

ChemoMetec A/S Stocks

DKK 362.2Last Updated 30.06.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

DKK 982.37M

DKK 362.2
Key Takeaways

Risk factor

Weak & very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Headquartered in Allerød, Denmark, and established in 1997, ChemoMetec A/S focuses on the design, production, and worldwide distribution of analytical instruments for cell enumeration and analysis. Their sophisticated solutions are utilized across diverse fields, including cell-based therapeutics, oncology and stem cell research, pharmaceutical development and manufacturing, along with quality assurance for animal semen and beer. The company's product offerings feature a range of NucleoCounter devices, such as the NC-3000 advanced image cytometer, the NC-250 automated cell analyzer, and the consistent NC-202 and NC-200 automated cell counters for viability assessment. Specialized counters include the NucleoCounter SP-100 for automated sperm cell analysis in animal production, the SCC-100 for measuring somatic cells in milk samples, and the YC-100 for total count and viability of yeast cells. Beyond equipment, they also supply vital consumables like cassettes and reagents, various accessories such as software and cables, and offer extensive service and validation plans.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of CHEMM.CO is 543 and suggests 48.6% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

01.07.2026 23:12

SpaceX Has Developed Its Own "AI Gadget" — WSJ

01.07.2026 22:17

Palantir has published a nine-point manifesto on the importance of “AI sovereignty”

01.07.2026 20:33

"A Key Source of Value and Risk": Wall Street's Top Tech Optimist Assesses SpaceX

01.07.2026 19:21

Companies laid off employees because of artificial intelligence. Some came to regret it.

01.07.2026 18:59

Meta will launch a cloud infrastructure business. It will compete with Google and Nebius

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026